AbbVie And Trump Administration Reach Deal To Expand Drug Access And Invest $100 Billion In U.S. Innovation

AbbVie has announced that the company has entered into a voluntary agreement with the Trump administration aimed at improving drug affordability and access for Americans while continuing to support U.S. pharmaceutical innovation. The deal is designed to strike a balance between lower patient costs and long-term investment in domestic research, development, and manufacturing.

Under the agreement, AbbVie will offer reduced pricing for its medicines within the Medicaid program and commit to investing $100 billion in U.S.-based research and development, as well as capital projects, over the next decade. The company will also expand its direct-to-patient distribution through the TrumpRx program, covering widely used medicines such as ALPHAGAN®, COMBIGAN®, HUMIRA®, and SYNTHROID®.

"AbbVie's mission is to make a remarkable impact for the patients we serve around the world through our innovative medicines," said Robert A. Michael, chairman and chief executive officer, AbbVie. "With approximately 29,000 U.S.-based employees and products treating 16 million Americans annually, we understand the complexity and access challenges in our healthcare system. AbbVie is following President Trump's call to action by reaching this agreement, allowing us to collectively move beyond policies that harm American innovation. Thank you to President Trump and his team for their leadership to help deliver cost savings and supporting our efforts to deliver innovative treatments for American patients."

The agreement addresses all four of the President’s drug pricing priorities and includes key provisions from the administration, including exemptions from tariffs and future price controls. In addition, the government will continue efforts to ensure that international drug prices more accurately reflect the value of U.S.-driven medical innovation, although other specific terms of the deal were not disclosed.

AbbVie stated that the partnership aligns with its mission to deliver innovative therapies across major disease areas, including immunology, oncology, neuroscience, and eye care, as well as through its Allergan Aesthetics portfolio, thereby making essential treatments more accessible to patients in the United States.